-
1.发明申请SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS 审中-公开取代的N-（1H-吲唑-4-基）咪唑并[1,2-A]吡啶-3-羧酰胺化合物作为CFMS抑制剂
公开(公告)号：WO2011079076A1
公开(公告)日：2011-06-30
申请号：PCT/US2010/061341
申请日：2010-12-20
Applicant: ARRAY BIOPHARMA INC. , BOYS, Mark Laurence , BRADLEY, Michael , DELISLE, Robert Kirk , HENNINGS, D. David , KENNEDY, April L. , MARMSATER, Fredrik P. , MEDINA, Matthew , MUNSON, Mark C. , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
Inventor： BOYS, Mark Laurence , BRADLEY, Michael , DELISLE, Robert Kirk , HENNINGS, D. David , KENNEDY, April L. , MARMSATER, Fredrik P. , MEDINA, Matthew , MUNSON, Mark C. , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , C07D519/00 , A61K31/437 , A61K31/4985 , A61P9/00 , A61P19/08 , A61P29/00 , A61P35/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.
Abstract translation: 其中R1，R2，R3，R4和R5具有本说明书中给出的含义的式（I）化合物及其药学上可接受的盐是cFMS的抑制剂，可用于治疗骨相关疾病，癌症，自身免疫 疾病，炎性疾病，心血管疾病和疼痛。
-
2.发明申请SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 审中-公开取代的N-（1H-咪唑-4-基）咪唑并[1,2-a]吡啶-3-羧酸酰胺化合物作为III型受体酪氨酸激酶抑制剂
公开(公告)号：WO2012082689A1
公开(公告)日：2012-06-21
申请号：PCT/US2011/064549
申请日：2011-12-13
Applicant: ARRAY BIOPHARMA INC. , BOYS, Mark Laurence , DELISLE, Robert Kirk , HICKEN, Erik James , KENNEDY, April L. , MARESKA, David A. , MARMSATER, Fredrik P. , MUNSON, Mark C. , NEWHOUSE, Brad , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
Inventor： BOYS, Mark Laurence , DELISLE, Robert Kirk , HICKEN, Erik James , KENNEDY, April L. , MARESKA, David A. , MARMSATER, Fredrik P. , MUNSON, Mark C. , NEWHOUSE, Brad , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Abstract translation: 式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6具有说明书中给出的含义，是cFMS的抑制剂，可用于治疗纤维化，骨相关疾病，癌症 ，自身免疫性疾病，炎性疾病，心血管疾病，哺乳动物的疼痛和灼伤。
-
公开(公告)号：WO2010022076A1
公开(公告)日：2010-02-25
申请号：PCT/US2009/054193
申请日：2009-08-18
Applicant: ARRAY BIOPHARMA INC. , ALLEN, Shelley , CELESTE, Laura L. , DAVIS, T. Gregg , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , GROSS, Stefan, D. , HICKEN, Erik, James , JACKSON, Leila, J. , LYSSIKATOS, Joseph, P. , KALLAN, Nicholas C. , MARMSATER, Fredrik, P. , MUNSON, Mark, C. , PHENEGER, Jed , RAST, Bryson , ROBINSON, John, E. , SCHLACHTER, Stephen T. , TOPALOV, George T. , WRIGHT, A. Dale , ZHAO, Qian
Inventor： ALLEN, Shelley , CELESTE, Laura L. , DAVIS, T. Gregg , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , GROSS, Stefan, D. , HICKEN, Erik, James , JACKSON, Leila, J. , LYSSIKATOS, Joseph, P. , KALLAN, Nicholas C. , MARMSATER, Fredrik, P. , MUNSON, Mark, C. , PHENEGER, Jed , RAST, Bryson , ROBINSON, John, E. , SCHLACHTER, Stephen T. , TOPALOV, George T. , WRIGHT, A. Dale , ZHAO, Qian
IPC: C07D471/04 , A61K31/47
CPC classification number: C07D471/04
Abstract: Compounds of Formula (I), in which A, B, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
Abstract translation: 其中A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有本说明书中给出的含义的式（I）化合物是可用于治疗免疫细胞相关的受体酪氨酸抑制剂 疾病和病症，如炎性和自身免疫性疾病。
-
公开(公告)号：WO2007027855A2
公开(公告)日：2007-03-08
申请号：PCT/US2006/033976
申请日：2006-08-31
Applicant: ARRAY BIOPHARMA INC. , MIKNIS, Greg , LYSSIKATOS, Joseph P. , LAIRD, Ellen , TARLTON, Eugene , BUCKMELTER, Alexandre J. , REN, Li , RAST, Bryson , SCHLACTER, Stephen T. , WENGLOWSKY, Steven Mark
Inventor： MIKNIS, Greg , LYSSIKATOS, Joseph P. , LAIRD, Ellen , TARLTON, Eugene , BUCKMELTER, Alexandre J. , REN, Li , RAST, Bryson , SCHLACTER, Stephen T. , WENGLOWSKY, Steven Mark
CPC classification number: C07D491/04 , C07D495/04
Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro , in situ , and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract translation: 式I的化合物可用于抑制Raf激酶和用于治疗由此介导的病症。 使用式I化合物及其立体异构体，几何异构体，互变异构体，溶剂合物及其药学上可接受的盐的方法用于在哺乳动物细胞或相关病理状况下的体外，原位和体内诊断，预防或治疗这些疾病。 披露。
-
公开(公告)号：EP1934228A2
公开(公告)日：2008-06-25
申请号：EP06813989.8
申请日：2006-08-31
Applicant: Array Biopharma, Inc.
Inventor： MIKNIS, Greg , LYSSIKATOS, Joseph P. , LAIRD, Ellen , TARLTON, Eugene , BUCKMELTER, Alexandre J. , REN, Li , RAST, Bryson , SCHLACTER, Stephen T. , WENGLOWSKY, Steven Mark
IPC: C07D495/04 , C07D491/04 , A61K31/4355 , A61K31/4365 , A61P35/00
CPC classification number: C07D491/04 , C07D495/04
Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
Patent Agency Ranking6.发明公开SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS 有权取代的N-（1H-吲唑-4-基）咪唑并+ AFS-1，2-A + AF0 - 吡啶-3-甲酰胺作为抑制剂CFMS
公开(公告)号：EP2516433A1
公开(公告)日：2012-10-31
申请号：EP10798683.8
申请日：2010-12-20
Applicant: Array Biopharma, Inc.
Inventor： BOYS, Mark Laurence , BRADLEY, Michael F. , DELISLE, Robert Kirk , HENNINGS, D. David , KENNEDY, April L. , MARMSATER, Fredrik P. , MEDINA, Matthew David , MUNSON, Mark C. , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , C07D519/00 , A61K31/437 , A61K31/4985 , A61P9/00 , A61P19/08 , A61P29/00 , A61P35/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R
1 , R
2 , R
3 , R
4 and R
5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.-
7.发明授权SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 有权取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-甲酰胺，为III型受体TYROSINKINASENHIBITOREN
公开(公告)号：EP2651939B1
公开(公告)日：2015-04-08
申请号：EP11808427.6
申请日：2011-12-13
Applicant: Array Biopharma, Inc.
Inventor： BOYS, Mark Laurence , DELISLE, Robert Kirk , HICKEN, Erik James , KENNEDY, April L. , MARESKA, David A. , MARMSATER, Fredrik P. , MUNSON, Mark C. , NEWHOUSE, Brad , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06
-
8.发明公开SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 有权取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-甲酰胺，为III型受体TYROSINKINASENHIBITOREN
公开(公告)号：EP2651939A1
公开(公告)日：2013-10-23
申请号：EP11808427.6
申请日：2011-12-13
Applicant: Array Biopharma, Inc.
Inventor： BOYS, Mark Laurence , DELISLE, Robert Kirk , HICKEN, Erik James , KENNEDY, April L. , MARESKA, David A. , MARMSATER, Fredrik P. , MUNSON, Mark C. , NEWHOUSE, Brad , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R
1 , R
2 , R
3 , R
4 , R
5 and R
6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.-
公开(公告)号：EP2334677B1
公开(公告)日：2013-10-09
申请号：EP09791625.8
申请日：2009-08-18
Applicant: Array Biopharma, Inc.
Inventor： ALLEN, Shelley , CELESTE, Laura L. , DAVIS, T. Gregg , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , GROSS, Stefan, D. , HICKEN, Erik, James , JACKSON, Leila, J. , LYSSIKATOS, Joseph, P. , KALLAN, Nicholas C. , MARMSATER, Fredrik, P. , MUNSON, Mark, C. , PHENEGER, Jed , RAST, Bryson , ROBINSON, John, E. , SCHLACHTER, Stephen T. , TOPALOV, George T. , WRIGHT, A. Dale , ZHAO, Qian
IPC: C07D471/04 , A61K31/47
CPC classification number: C07D471/04
-
公开(公告)号：EP2334677A1
公开(公告)日：2011-06-22
申请号：EP09791625.8
申请日：2009-08-18
Applicant: Array Biopharma, Inc.
Inventor： ALLEN, Shelley , CELESTE, Laura L. , DAVIS, T. Gregg , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , GROSS, Stefan, D. , HICKEN, Erik, James , JACKSON, Leila, J. , LYSSIKATOS, Joseph, P. , KALLAN, Nicholas C. , MARMSATER, Fredrik, P. , MUNSON, Mark, C. , PHENEGER, Jed , RAST, Bryson , ROBINSON, John, E. , SCHLACHTER, Stephen T. , TOPALOV, George T. , WRIGHT, A. Dale , ZHAO, Qian
IPC: C07D471/04 , A61K31/47
CPC classification number: C07D471/04
Abstract: Compounds of Formula (I), in which A, B, R
1 , R
1a , R
2 , R
3 , R
4 , R
5 , R
6 , and R
7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.Abstract translation: 其中A，B，R 1，R 1a，R 2，R 3，R 4，R 5，R 6和R 7具有说明书中给出的含义的式（I）化合物是有用的受体酪氨酸抑制剂 用于治疗免疫细胞相关疾病和病症，例如炎性和自身免疫性疾病。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.031 seconds)
